Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis

Journal of Immunology

Volumn 186, Issue 11, 2011, Pages 6633-6640

  James, Eddie A ^a   DeVoti, James A ^b,c   Rosenthal, David W ^b,c   Hatam, Lynda J ^b,c   Steinberg, Bettie M ^b,c,d   Abramson, Allan L ^b,c,d   Kwok, William W ^a,e   Bonagura, Vincent R ^b,c  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c Northwell Health   (United States)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 13; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN E2; PROTEIN E6; STAT5 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN V;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL POLARITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; IMMUNE RESPONSE; PAPILLOMATOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECURRENT RESPIRATORY PAPILLOMATOSIS; RESPIRATORY TRACT TUMOR; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 11; INTERFERON-GAMMA; INTERLEUKIN-13; INTERLEUKIN-2; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PEPTIDES; PHOSPHORYLATION; RESPIRATORY TRACT INFECTIONS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS;

EID: 79958039246     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1004181     Document Type: Article

References (47)

1. Welters, M. J., A. de Jong, S. J. van den Eeden, J. M. van der Hulst, K. M. Kwappenberg, S. Hassane, K. L. Franken, J. W. Drijfhout, G. J. Fleuren, G. Kenter, et al. 2003. Frequent display of human papillomavirus type 16 E6- specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 63: 636-641.
2. Broker, T. R., G. Jin, A. Croom-Rivers, S. M. Bragg, M. Richardson, L. T. Chow, S. H. Vermund, R. D. Alvarez, P. G. Pappas, K. E. Squires, and C. J. Hoesley. 2001. Viral latency - the papillomavirus model. Dev. Biol. (Basel) 106: 443-451, discussion 452-453, 465-475.
3. Schiffman, M., and P. E. Castle. 2003. Human papillomavirus: epidemiology and public health. Arch. Pathol. Lab. Med. 127: 930-934.
4. Zacharisen, M. C., and S. F. Conley. 2006. Recurrent respiratory papillomatosis in children: masquerader of common respiratory diseases. Pediatrics 118: 1925-1931.
5. Armstrong, L. R., E. J. Preston, M. Reichert, D. L. Phillips, R. Nisenbaum, N. W. Todd, I. N. Jacobs, A. F. Inglis, S. C. Manning, and W. C. Reeves. 2000. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin. Infect. Dis. 31: 107-109.
6. Gissmann, L., L. Wolnik, H. Ikenberg, U. Koldovsky, H. G. Schnürch, and H. zur Hausen. 1983. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc. Natl. Acad. Sci. USA 80: 560-563.
7. Derkay, C. S., and B. Wiatrak. 2008. Recurrent respiratory papillomatosis: a review. Laryngoscope 118: 1236-1247.
8. Steinberg, B. M., T. Gallagher, M. Stoler, and A. L. Abramson. 1988. Persistence and expression of human papillomavirus during interferon therapy. Arch. Otolaryngol. Head Neck Surg. 114: 27-32.
9. Nakagawa, M., D. P. Stites, S. Patel, S. Farhat, M. Scott, N. K. Hills, J. M. Palefsky, and A. B. Moscicki. 2000. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J. Infect. Dis. 182: 595-598.
10. Sheu, B. C., R. H. Lin, H. C. Lien, H. N. Ho, S. M. Hsu, and S. C. Huang. 2001. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J. Immunol. 167: 2972-2978.
11. DeVoti, J. A., B. M. Steinberg, D. W. Rosenthal, L. Hatam, A. Vambutas, A. L. Abramson, M. J. Shikowitz, and V. R. Bonagura. 2004. Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis. Clin. Diagn. Lab. Immunol. 11: 538-547.
12. Scott, M., M. Nakagawa, and A. B. Moscicki. 2001. Cell-mediated immune response to human papillomavirus infection. Clin. Diagn. Lab. Immunol. 8: 209-220.
13. Brandsma, J. L., M. Shylankevich, Y. Su, A. Roberts, J. K. Rose, D. Zelterman, and L. Buonocore. 2007. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J. Virol. 81: 5749-5758.
14. Brandsma, J. L., M. Shlyankevich, L. Zhang, M. D. Slade, E. C. Goodwin, W. Peh, and A. B. Deisseroth. 2004. Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J. Virol. 78: 116-123.
15. de Jong, A., T. O'Neill, A. Y. Khan, K. M. Kwappenberg, S. E. Chisholm, N. R. Whittle, J. A. Dobson, L. C. Jack, J. A. St Clair Roberts, R. Offringa, et al. 2002. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20: 3456-3464.
16. Vambutas, A., J. DeVoti, M. Nouri, J. W. Drijfhout, G. B. Lipford, V. R. Bonagura, S. H. van der Burg, and C. J. Melief. 2005. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 23: 5271-5280.
17. Bonagura, V. R., A. Vambutas, J. A. DeVoti, D. W. Rosenthal, B. M. Steinberg, A. L. Abramson, M. J. Shikowitz, D. W. Gjertson, and E. F. Reed. 2004. HLA alleles, IFN-gamma responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis. Hum. Immunol. 65: 773-782.
18. Kim, P. S., and R. Ahmed. 2010. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22: 223-230.
19. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334.
20. Novak, E. J., A. W. Liu, G. T. Nepom, and W. W. Kwok. 1999. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104: R63-R67.
21. James, E. A., A. K. Moustakas, D. Berger, L. Huston, G. K. Papadopoulos, and W. W. Kwok. 2008. Definition of the peptide binding motif within DRB1*1401 restricted epitopes by peptide competition and structural modeling. Mol. Immunol. 45: 2651-2659.
22. Novak, E. J., A. W. Liu, J. A. Gebe, B. A. Falk, G. T. Nepom, D. M. Koelle, and W. W. Kwok. 2001. Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens. J. Immunol. 166: 6665-6670.
23. James, E. A., J. Bui, D. Berger, L. Huston, M. Roti, and W. W. Kwok. 2007. Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int. Immunol. 19: 1291-1301.
24. Long, S. A., K. Cerosaletti, P. L. Bollyky, M. Tatum, H. Shilling, S. Zhang, Z. Y. Zhang, C. Pihoker, S. Sanda, C. Greenbaum, and J. H. Buckner. 2010. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 59: 407-415.
25. Verreck, F. A., A. van de Poel, J. W. Drijfhout, R. Amons, J. E. Coligan, and F. Konig. 1996. Natural peptides isolated from Gly86/Val86-containing variants of HLA-DR1, -DR11, -DR13, and -DR52. Immunogenetics 43: 392-397.
26. Geluk, A., K. E. van Meijgaarden, S. Southwood, C. Oseroff, J. W. Drijfhout, R. R. de Vries, T. H. Ottenhoff, and A. Sette. 1994. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J. Immunol. 152: 5742-5748. (Pubitemid 24174153)
27. Abramson, A. L., B. M. Steinberg, and B. Winkler. 1987. Laryngeal papillomatosis: clinical, histopathologic and molecular studies. Laryngoscope 97: 678-685. (Pubitemid 17085917)
28. Bonnez, W., H. K. Kashima, B. Leventhal, P. Mounts, R. C. Rose, R. C. Reichman, and K. V. Shah. 1992. Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP). Virology 188: 384-387.
29. Seresini, S., M. Origoni, F. Lillo, L. Caputo, A. M. Paganoni, S. Vantini, R. Longhi, G. Taccagni, A. Ferrari, C. Doglioni, et al. 2007. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. J. Immunol. 179: 7176-7183.
30. de Jong, A., M. I. van Poelgeest, J. M. van der Hulst, J. W. Drijfhout, G. J. Fleuren, C. J. Melief, G. Kenter, R. Offringa, and S. H. van der Burg. 2004. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 64: 5449-5455.
31. de Jong, A., S. H. van der Burg, K. M. Kwappenberg, J. M. van der Hulst, K. L. Franken, A. Geluk, K. E. van Meijgaarden, J. W. Drijfhout, G. Kenter, P. Vermeij, et al. 2002. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 62: 472-479.
32. Bonagura, V. R., F. P. Siegal, A. L. Abramson, F. Santiago-Schwarz, M. E. O'Reilly, K. Shah, D. Drake, and B. M. Steinberg. 1994. Enriched HLA-DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis. Clin. Diagn. Lab. Immunol. 1: 357-360.
33. Bonagura, V. R., L. J. Hatam, D. W. Rosenthal, J. A. de Voti, F. Lam, B. M. Steinberg, and A. L. Abramson. 2010. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS 118: 455-470.
34. Stanley, M. 2008. Immunobiology of HPV and HPV vaccines. Gynecol. Oncol. 109(2 Suppl):S15-S21.
35. Melero, I., M. C. Singhal, P. McGowan, H. S. Haugen, J. Blake, K. E. Hellstrom, G. Yang, C. H. Clegg, and L. Chen. 1997. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71: 3998-4004. (Pubitemid 27172415)
36. Stolina, M., S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P. W. Miller, J. Portanova, et al. 2000. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164: 361-370. (Pubitemid 30013010)
37. Bonagura, V. R., L. Hatam, J. DeVoti, F. Zeng, and B. M. Steinberg. 1999. Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and T(H)1/T (H)2 cytokine imbalance. Clin. Immunol. 93: 302-311.
38. Yi, J. S., M. A. Cox, and A. J. Zajac. 2010. T-cell exhaustion: characteristics, causes and conversion. Immunology 129: 474-481.
39. Steinberg, T., P. Ohlschläger, P. Sehr, W. Osen, and L. Gissmann. 2005. Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. Vaccine 23: 1149-1157. (Pubitemid 40052011)
40. D'Souza, M., A. P. Fontenot, D. G. Mack, C. Lozupone, S. Dillon, A. Meditz, C. C. Wilson, E. Connick, and B. E. Palmer. 2007. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J. Immunol. 179: 1979-1987.
41. Choi, S., and R. H. Schwartz. 2007. Molecular mechanisms for adaptive tolerance and other T cell anergy models. Semin. Immunol. 19: 140-152.
42. Anderson, K. M., S. J. Czinn, R. W. Redline, and T. G. Blanchard. 2006. Induction of CTLA-4-mediated anergy contributes to persistent colonization in the murine model of gastric Helicobacter pylori infection. J. Immunol. 176: 5306-5313.
43. Inobe, M., and R. H. Schwartz. 2004. CTLA-4 engagement acts as a brake on CD4+ T cell proliferation and cytokine production but is not required for tuning T cell reactivity in adaptive tolerance. J. Immunol. 173: 7239-7248.
44. Frauwirth, K. A., M. L. Alegre, and C. B. Thompson. 2000. Induction of T cell anergy in the absence of CTLA-4/B7 interaction. J. Immunol. 164: 2987-2993.
45. Healy, G. B., R. D. Gelber, A. L. Trowbridge, K. M. Grundfast, R. J. Ruben, and K. N. Price. 1988. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N. Engl. J. Med. 319: 401-407.
46. Mullooly, V. M., A. L. Abramson, B. M. Steinberg, and M. S. Horowitz. 1988. Clinical effects of alpha-interferon dose variation on laryngeal papillomas. Laryngoscope 98: 1324-1329.
47. Leventhal, B. G., H. K. Kashima, P. Mounts, L. Thurmond, S. Chapman, S. Buckley, D. Wold; Papilloma Study Group. 1991. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1. N. Engl. J. Med. 325: 613-617.